News

A company that manufactures many types of drugs has submitted plans to expand its campus in Worcester. AbbVie has filed a ...
A lack of enough hospital beds during times of high demand has caused “significant backups in the Emergency Department.” ...
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron announced the purchase Monday. In March, 23andMe initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court to be sold. 23andMe offers DNA testing with an ancestry breakdown ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.
Regeneron intends for 23andMe to continue its consumer genome services without interruption. The transaction, pending bankruptcy court and regulatory approvals, is expected to close in the third ...
With its winning offer, Regeneron outbid 23andMe’s former CEO and co-founder, Anne Wojcicki, who has been angling to take the DNA tester private for over a year. Wojcicki first announced her ...
Reuters The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.
Despite the news of the purchase, Regeneron’s stock was down 0.6 percent from the market open on Wall Street as of 12pm in New York (16:00 GMT) although it had gone up 2.86 percent over the ...
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...